Browse the evidence

Promotional strategies in supermarkets, including folder offers and in-store placements (end-caps, impulse displays), heavily favor unhealthy products, with 81% of promoted items falling outside healthy dietary guidelines.

Be cautious of promotions and in-store placements, as they are designed to sell unhealthy products. 81% of promoted items do not meet healthy dietary guidelines. To eat healthily, avoid impulse buys and promotions, and stick to a shopping list of healthy items.

The incidence of allergic reactions to mycoprotein is exceptionally low (1 in 9 million packages) compared to common allergens, making it a safe novel protein source.

You can safely consume mycoprotein. The risk of an allergic reaction is extremely low (1 in 9 million packages), making it a safe option for most people.

The effectiveness of taste-focused labeling is moderated by the average tastiness of the vegetable recipes served in a specific dining hall; labeling is less effective or ineffective in settings where vegetables are perceived as less tasty.

Taste-focused labeling is most effective when the underlying food is actually good. If vegetables are poorly prepared, taste-focused labels may fail to increase consumption. Ensure the base recipe is palatable before relying on labeling strategies.

A government-supported 'soft regulation' policy combining industry agreements and public education to reduce sodium intake by 10% over 10 years is highly cost-effective globally, averting millions of disability-adjusted life years (DALYs) at a mean cost of approximately I$204 per DALY saved.

Governments can significantly reduce cardiovascular disease and save lives by implementing a 'soft regulation' policy that encourages food manufacturers to lower sodium in processed foods, supported by public education. This approach is highly cost-effective, costing roughly $204 per disability-adjusted life year saved, which is well below standard thresholds for cost-effective interventions. Even in high-income countries, it remains a 'best buy' for public health.

Adherence to guideline-recommended physical activity (150 min moderate or 75 min vigorous aerobic activity per week) is strongly associated with higher cardiorespiratory fitness (VO2peak) in patients with Type 2 Diabetes Mellitus, yet less than half of this high-risk population achieves these guidelines.

For patients with Type 2 Diabetes, simply moving around (light activity) is not enough to improve heart health or fitness. You must engage in at least 150 minutes of moderate-intensity aerobic activity (like brisk walking) or 75 minutes of vigorous activity (like jogging) per week. Most patients fail to do this, leading to low fitness levels. Focus on intensity, not just total movement.

Short sleep duration (<5 hours) and long sleep duration (>9 hours) are independently associated with a significantly increased risk of acute stroke, exhibiting a U-shaped relationship where short sleep shows a higher magnitude of association on univariate analysis but attenuates more than long sleep after adjusting for comorbidities.

Aim for 7 hours of sleep per night. Both sleeping less than 5 hours and more than 9 hours is associated with a significantly higher risk of stroke. If you consistently sleep outside this range, consider it a modifiable risk factor for cardiovascular health, especially if you have other risk factors like hypertension.

Symptoms of Obstructive Sleep Apnea (snoring, snorting, breathing cessation) and a derived OSA score of 2-3 are significantly associated with increased odds of acute stroke, independent of a formal OSA diagnosis.

If you or your partner notice loud snoring, gasping, or pauses in breathing during sleep, seek medical evaluation. These symptoms are strongly linked to stroke risk, even if you haven't been diagnosed with sleep apnea. Addressing these symptoms may reduce stroke risk.

A higher cumulative burden of sleep disturbance symptoms (Sleep Disturbance Symptom Burden >5) is associated with a graded, significantly increased risk of acute stroke, with the highest burden showing an OR of 5.38.

If you experience multiple sleep problems (e.g., short/long sleep, poor quality, snoring, napping), your stroke risk increases significantly. The more symptoms you have, the higher the risk. Seek a comprehensive sleep evaluation to address all symptoms, not just one.

Lifestyle interventions alone are difficult to maintain long-term for weight loss in patients with T2DM and CKD, whereas GLP-1 RAs offer a pharmacological alternative with proven metabolic and organ protection benefits.

While lifestyle changes are important, they are hard to keep up long-term. GLP-1 RAs can help you maintain weight loss and protect your heart and kidneys, making it easier to stick to healthy habits. Talk to your doctor about whether a GLP-1 RA is right for you.

Binge eating behaviors reduce the efficacy of weight loss interventions in type 2 diabetes, and dieting itself can be a risk factor for the onset of binge eating.

Be aware that restrictive dieting can trigger binge eating in some patients with type 2 diabetes. If binge eating is present, it will hinder weight loss success. Address this by avoiding punitive language and focusing on positive, varied food choices rather than strict restriction.

Anti-obesity medications (AOMs) including GLP-1 receptor agonists (liraglutide, semaglutide) and other agents (naltrexone-bupropion, phentermine-topiramate, orlistat) are significantly underutilized in clinical practice, with only 8% of eligible patients receiving a prescription and 4.4% filling it.

If you have obesity (BMI ≥30) and are interested in anti-obesity medications (AOMs) like GLP-1 agonists (e.g., semaglutide, liraglutide), be aware that access is heavily restricted by insurance type and demographics. In this study, only 8% of eligible patients got a prescription, and 4.4% filled it. If you are insured by Medicaid, Medicare, or are a minority, you face significantly lower odds of receiving these medications. Discuss these barriers with your provider and advocate for coverage options, as private insurance offers better access than public programs.

Obesity is associated with decreased prefrontal cortex activity and decreases in goal-directed decision-making, which influences food intake.

Recognize that obesity involves physiological changes in the brain, specifically decreased prefrontal cortex activity and goal-directed decision-making. This means relying solely on willpower is biologically harder for individuals with obesity, and strategies should account for these neural differences (e.g., environmental changes, behavioral training).

Educational documentaries can significantly increase intentions to reduce meat consumption, but these increased intentions do not translate into reduced actual consumption.

You can watch a documentary and genuinely *want* to eat less meat, but that desire alone won't change your diet. The study shows that while intentions go up, actual eating habits stay the same. To bridge this gap, you need more than just motivation; you need a plan, recipes, and environmental support to turn that intention into action.

Discontinuation rates for weight-reducing (WR) diabetes-specific medications are nearly twice as high as those for weight-inducing (WI) medications, indicating poor persistence with preferred therapies.

If you start a weight-reducing diabetes medication, be prepared for a higher chance of stopping it compared to older weight-gain drugs. This is common, so don't be discouraged. Talk to your doctor about managing side effects, starting with a lower dose, or switching to an oral formulation if injections are the issue. Persistence is key to seeing long-term benefits.

Higher BMI is associated with increased feelings of being judged by primary care providers, which correlates with higher rates of avoiding healthcare visits due to weight-related concerns.

If you have a higher BMI, you may feel judged by doctors, and this feeling often stops you from going to appointments. This is a common reaction to stigma, not a reflection of your worth. To overcome this, look for providers who explicitly prioritize respectful communication and ask about your weight management goals proactively.

Food cravings and medical conditions limiting physical activity are the most frequent barriers to weight loss, with food cravings reported by 30.7%-49.9% of respondents.

Food cravings and physical limitations are the top barriers to weight loss for most people. These are common and can often be addressed through education and access to resources like dietitians and exercise facilities.

Implementing an intensive 18-month behavioral weight loss intervention in community mental health settings for adults with serious mental illness costs approximately $501 per kilogram of weight lost, or $95 per participant per month.

If you run a community mental health program, you can implement an 18-month weight loss program for about $95 per patient per month. The key is to use existing staff and kitchen budgets where possible, and to train your own staff to deliver the intervention to save on hiring external coaches. The cost per kilogram lost is competitive with commercial programs, making it a viable option for improving patient health.

An academia-industry partnership model for community-based controlled feeding studies enables high-fidelity macronutrient differentiation and long-term adherence, overcoming the feasibility and cost barriers of traditional hospital-based metabolic ward trials.

This paper does not offer a direct diet plan for individuals, but it validates that high-adherence dietary interventions are possible in real-world settings if logistical barriers are removed. For researchers or program designers, partnering with commercial food services (like Sodexo) allows for the creation of palatable, differentiated diets that participants can actually follow long-term. For individuals, the key takeaway is that removing the burden of meal planning and procurement (via meal delivery or similar services) significantly improves adherence to specific macronutrient targets.

A six-month home-based physical activity and nutrition intervention produces significant improvements in metabolic syndrome parameters, but these benefits largely plateau and do not significantly improve further during an 18-month follow-up without additional booster interventions.

If you start a health program, expect the biggest changes in the first 6 months. To keep those gains, you cannot just stop. You need a 'maintenance mode' plan with regular check-ins, even if they are brief, to prevent your habits from slowly drifting back to old patterns.

Urban design that promotes physical activity and provides green space reduces cardiovascular mortality and risk factors, whereas urban environments that hinder activity and lack green space increase risk.

Prioritize living in or visiting areas with significant tree canopy and green space. If you live in a dense urban area, seek out parks and green corridors. These spaces not only encourage physical activity but also mitigate heat stress and air pollution, directly lowering cardiovascular risk.

Significant initial weight loss (decrease in BMI) is a strong predictor of high adherence to liraglutide treatment.

If you experience significant weight loss in the first few months of liraglutide treatment, you are much more likely to stick with the medication long-term. This positive feedback loop is a key factor in maintaining adherence.

Higher socioeconomic status and non-smoking status are significantly associated with higher adherence to liraglutide treatment.

Patients with higher income/education levels and those who do not smoke are more likely to adhere to their liraglutide prescription. Addressing financial barriers and supporting smoking cessation may improve adherence rates.

The brain utilizes two distinct, opponent neural networks to process food cues: a Limbic network that automatically encodes hedonic value (pleasantness/appetite), and a Prefrontal network that encodes regulatory information (healthfulness, processing level, and self-control requirements).

When you see food, your brain automatically splits the information: one part tells you how good it tastes (Limbic), and another tells you how processed/healthy it is (Prefrontal). To make better choices, consciously engage the Prefrontal network by focusing on the food's processing level or health attributes, rather than just fighting the taste. This leverages the brain's natural regulatory architecture.

The semaglutide 2.4 mg single-dose pen-injector (SPI) demonstrates high ease-of-use and acceptability, with the vast majority of participants finding it easy to use and training, and preferring it over daily oral medication.

If you are considering semaglutide 2.4 mg via the single-dose pen, expect it to be easy to use. Most users found the training simple and the injection process easy. While some initial use errors (like seeing liquid on the skin) can occur, they are common in the first few injections and tend to disappear with practice. The device is generally preferred over daily pills due to its weekly frequency and ease of use.